Cite
HARVARD Citation
Harris, D. et al. (n.d.). 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. Journal for immunotherapy of cancer. pp. A242-A243. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Harris, D. et al. (n.d.). 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. Journal for immunotherapy of cancer. pp. A242-A243. [Online].